Article Information
History
- February 22, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Jonathan D. Herman1,2,*,
- Chuangqi Wang3,*,
- John Stephen Burke1,
- Yonatan Zur1,
- Hacheming Compere1,
- Jaewon Kang1,
- Ryan Macvicar1,
- Sally Shin1,
- Ian Frank4,
- Don Siegel5,
- Pablo Tebas4,
- Grace H. Choi6,
- Pamela A. Shaw7,
- Hyunah Yoon8,
- Liise-anne Pirofski8,9,
- Boris Juelg1,
- Katharine J. Bar4,†,
- Douglas Lauffenburger3,† and
- Galit Alter1,†
- 1Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA
- 2Division of Infectious Disease, Brigham and Women’s Hospital, Boston, MA, USA
- 3Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
- 4Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
- 5Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA
- 6Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, USA
- 7Kaiser Permanente Washington Health Research Group, Seattle, WA 98101
- 8Division of Infectious Diseases, Department of Medicine. Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA
- 9Department of Microbiology and Immunology. Albert Einstein College of Medicine, Bronx, NY, USA
- ↵†Corresponding authors: Katharine J. Bar, MD: bark{at}pennmedicine.upenn.edu, Douglas Lauffenburger, PhD: lauffen{at}mit.edu, Galit Alter, PhD: galter{at}mgh.harvard.edu
↵* Equal contribution
Posted February 22, 2022.
A role for Nucleocapsid-specific antibody function in Covid-19 Convalescent plasma therapy
